Valeritas, which markets a disposable device that delivers basal-bolus insulin therapy for Type 2 diabetes, filed on Monday with the SEC to raise up to $50 million in an initial public offering. It previously filed for a $75 million IPO in February 2015.
The Bridgewater, NJ-based company was founded in 2006 and booked $19 million in sales for the 12 months ended September 30, 2016. It plans to list on the Nasdaq under the symbol VLRX. Cowen & Company and Wedbush PacGrow are the joint bookrunners on the deal. No pricing terms were disclosed.
